STXS logo

STXS
Stereotaxis Inc

2,041
Mkt Cap
$178.94M
Volume
173,658.00
52W High
$3.59
52W Low
$1.54
PE Ratio
-7.31
STXS Fundamentals
Price
$1.82
Prev Close
$1.84
Open
$1.80
50D MA
$2.21
Beta
1.14
Avg. Volume
472,971.73
EPS (Annual)
-$0.2519
P/B
13.01
Rev/Employee
$247,152.67
$206.46
Loading...
Loading...
News
all
press releases
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +5.21% and -5.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
More News
News Placeholder
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +44.83% and +0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Can Digital Subscriptions Become ISRG's New Revenue Stream in 2026?
Intuitive Surgical's My Intuitive+ may turn paid in 2026, adding a software-driven revenue layer as renewals begin and digital engagement scales.
Zacks·21d ago
News Placeholder
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +29.73% and +4.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago
News Placeholder
TransMedics (TMDX) Beats Q4 Earnings and Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of +40.02% and +3.11%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·28d ago
News Placeholder
Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +28.57% and +0.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
ISRG's da Vinci 5 begins international rollout, but pricing sensitivity, budgets, and reimbursement hurdles could slow adoption outside the United States.
Zacks·2mo ago
News Placeholder
Is ISRG's 20% Procedure Growth the New Normal or a Peak?
ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.
Zacks·3mo ago
News Placeholder
From Hospitals to ASCs: Will Refurbished Xi Systems Broaden ISRG's Reach?
ISRG leverages refurbished Xi systems to reach cost-sensitive markets and expand access beyond hospitals.
Zacks·4mo ago
News Placeholder
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
Zacks·4mo ago
<
1
2
...
>

Latest STXS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.